■这项研究调查了持续COVID-19测试阳性患者的恢复期血浆治疗与转阴率之间的关系。
■对病毒核酸检测阳性超过30天的重度或轻度至中度COVID-19患者进行了回顾性分析。患者分为两组:给予恢复期血浆疗法的患者和未给予恢复期血浆疗法的患者。收集的数据包括使用的治疗策略的信息(恢复期血浆,皮质类固醇,干扰素,等。),患者的人口统计学特征,合并症,治疗药物,和核酸检测结果。恢复期血浆治疗组的患者与非恢复期血浆治疗组的患者的比例为1:2。第五次累积负转化率,第十,和治疗开始后第15天作为因变量进行分析.独立变量包括治疗策略,人口特征,合并症,和治疗药物的使用。进行了单变量分析,并且p值(P)小于0.2的因子被纳入配对的Cox比例风险模型.
■第5次恢复期血浆治疗组和非恢复期血浆治疗组的累积转阴率无统计学差异,第十,第十五天。具体来说,第五天,恢复期血浆治疗组的阴转率为41.46%,而非恢复期血浆治疗组为34.15%(HR:1.72,95%CI:0.82~3.61,P=0.15).第十天,恢复期血浆治疗组为63.41%,非恢复期血浆治疗组为63.41%(HR:1.25,95%CI:0.69~2.26,P=0.46)。在第十五天,恢复期血浆治疗组的阴转率为85.37%,非恢复期血浆治疗组为75.61%(HR:1.19,95%CI:0.71~1.97,P=0.51).
■我们的发现不支持以下假设:恢复期血浆治疗可加速持续检测为COVID-19阳性的患者的阴性转化时间。
UNASSIGNED: This study investigates the association between convalescent plasma therapy and the negative conversion rate in patients with persistent COVID-19 test positivity.
UNASSIGNED: A retrospective analysis was conducted on patients with severe or mild to moderate COVID-19 whose viral nucleic acid tests remained positive for over 30 days. Patients were categorized into two groups: those who administered convalescent plasma therapy and those who were not. Data collected included information on therapy strategies used (convalescent plasma, corticosteroids, interferons, etc.), patients\' demographic characteristics, comorbidities, therapeutic medications, and nucleic acid testing results. Patients in the convalescent plasma therapy group were matched 1:2 ratio with those in the non-convalescent plasma therapy group. Cumulative negative conversion rates on the fifth, tenth, and fifteenth days post-therapy initiation were analyzed as dependent variables. Independent variables included therapy strategies, demographic characteristics, comorbidities, and therapeutic medication usage. Univariate analysis was conducted, and factors with a p-value (P) less than 0.2 were included in a paired Cox proportional hazards model.
UNASSIGNED: There was no statistically significant difference in the cumulative negative conversion rate between the convalescent plasma therapy group and the non-convalescent plasma therapy group on the fifth, tenth, and fifteenth days. Specifically, on day the fifth, the negative conversion rate was 41.46% in the convalescent plasma therapy group compared to 34.15% in the non-convalescent plasma therapy group (HR: 1.72, 95% CI: 0.82-3.61, P = 0.15). On the tenth day, it was 63.41% in the convalescent plasma therapy group and 63.41% in the non-convalescent plasma therapy group (HR: 1.25, 95% CI: 0.69∼2.26, P = 0.46). On the fifteenth day, the negative conversion rate was 85.37% in the convalescent plasma therapy group and 75.61% in the non-convalescent plasma therapy group (HR: 1.19, 95% CI: 0.71-1.97, P = 0.51).
UNASSIGNED: Our finding does not support the hypothesis that convalescent plasma therapy could accelerate the time to negative conversion in patients who consistently test positive for COVID-19.